Trial · NCT03026166
Adverse events336
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 336
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Cohort 1: Rovalpituzumab Tesirine and Nivolumab | 10 | 30 | 17 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 2: Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | 6 | 12 | 6 |
| other | Leukocytosis | Blood and lymphatic system disorders | Cohort 1: Rovalpituzumab Tesirine and Nivolumab | 1 | 30 | 1 |
| other | Leukocytosis | Blood and lymphatic system disorders | Cohort 2: Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | 1 | 12 | 1 |
| other | Lymphopenia | Blood and lymphatic system disorders | Cohort 1: Rovalpituzumab Tesirine and Nivolumab | 2 | 30 | 2 |
| other | Lymphopenia | Blood and lymphatic system disorders | Cohort 2: Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | 0 | 12 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | Cohort 1: Rovalpituzumab Tesirine and Nivolumab | 1 | 30 | 1 |
| other | Neutropenia | Blood and lymphatic system disorders | Cohort 2: Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | 2 | 12 | 2 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Cohort 1: Rovalpituzumab Tesirine and Nivolumab | 9 | 30 | 14 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Cohort 2: Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | 5 | 12 | 7 |
| other | Atrial fibrillation | Cardiac disorders | Cohort 1: Rovalpituzumab Tesirine and Nivolumab | 3 | 30 | 3 |
| other | Atrial fibrillation | Cardiac disorders | Cohort 2: Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | 0 | 12 | 0 |
| other | Palpitations | Cardiac disorders | Cohort 1: Rovalpituzumab Tesirine and Nivolumab | 0 | 30 | 0 |
| other | Palpitations | Cardiac disorders | Cohort 2: Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | 1 | 12 | 1 |
| other | Pericardial effusion | Cardiac disorders | Cohort 1: Rovalpituzumab Tesirine and Nivolumab | 7 | 30 | 8 |
| other | Pericardial effusion | Cardiac disorders | Cohort 2: Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | 1 | 12 | 2 |
| other | Sinus tachycardia | Cardiac disorders | Cohort 1: Rovalpituzumab Tesirine and Nivolumab | 3 | 30 | 3 |
| other | Sinus tachycardia | Cardiac disorders | Cohort 2: Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | 0 | 12 | 0 |
| other | Tachycardia | Cardiac disorders | Cohort 1: Rovalpituzumab Tesirine and Nivolumab | 2 | 30 | 2 |
| other | Tachycardia | Cardiac disorders | Cohort 2: Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | 1 | 12 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03026166/events